FEDERAL SECURITY AGENCY
PUBLIC HEALTH SERVICE
LEXINGTON, KENTUCKY

26 October 1953

IN REPLYING, ADDRESS THE
[redacted]
PUBLIC HEALTH SERVICE HOSPITAL
NIMH Addiction Research Center

[redacted]

21

(b)(3)

I am enclosing a copy of our quarterly report for your information. You will be chiefly interested in the material beginning on Page 7, 17, and 19. We are now beginning preliminary work with the monoethylamide of lysergic acid (LAE-32), but probably studies with this compound will not be extensive.

I have had a letter from the Sandoz company indicating that they will prepare a gram of LSD-25 for $200.00 and I have ordered this material. This should be ample for any future work contemplated, including animal neurophysiology. I might suggest that persons who are interested in this drug might write to Sandoz, since it would seem likely the company would prefer to make a larger batch of the material for sale to all who are interested.

I have become interested in doing some preliminary experiments with chloropromazine, a phenothiazine derivative developed in France, but which can be obtained through Smith-Kline and French. The European clinical literature states that this material is a powerful sedative drug which produces profound effects on the autonomic nervous system as well. Smith-Kline and French has already promised me a supply.

I will attend the meeting of the Drug Addiction Committee in Boston on November 6th and 7th. If circumstances permit, I may stop in Washington during the following week. I cannot be sure of the date, since it is also possible that I may have to attend a meeting in New York following the meeting of the Drug Addiction Committee.

Very sincerely yours,

Harris Isbell, M.D.
Director of Research

HI:rn

Enclosure

[redacted]

Declassified by 187473
date 4 FEB 1977